Scarica l'app Stockscreener
7.78
0.39%
0.03
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Wellington Management Group LLP Buys Shares of 82,596 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Teva loses US appeal to keep inhaler patents on FDA protected drug list - Reuters.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5%Here's What Happened - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average Price Target from Analysts - MarketBeat
BNP Paribas Financial Markets Sells 402,852 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com
Parkinson's Disease Market to Reach New Heights in Growth - openPR
SERD Therapeutics Market Key Players AnalysisAmneal - openPR
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Jacobs Levy Equity Management Inc. Sells 189,881 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Charles Schwab Investment Management Inc. Buys 202,863 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Walleye Capital LLC Invests $1.10 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
Amneal to Participate at Upcoming Investor Conferences - BioSpace
Amneal Pharmaceuticals Leadership to Present at Major Healthcare Investment Conferences - StockTitan
Quantbot Technologies LP Grows Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals director John Kiely sells $142,946 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals director John Kiely sells $142,946 in stock - Investing.com India
Insider Sell: Deborah Autor Sells 40,000 Shares of Amneal Pharma - GuruFocus.com
Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 - GlobeNewswire Inc.
Amneal Set To Debut US Byetta Competition – Two Decades After Market Entry - Citeline
Premature Ejaculation Treatment Market to Grow by USD 1.46 Billion (2024-2028), Boosted by Effective Off-Label Drugs, Market Evolution Powered by AITechnavio - The Malaysian Reserve
Amneal Pharmaceuticals exec sells shares worth $114,786 - Investing.com India
Amneal Pharmaceuticals exec sells shares worth $114,786 By Investing.com - Investing.com Nigeria
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Amneal files again for FDA approval of first dihydroergotamine autoinjector - Pharmaceutical Technology
Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide By Investing.com - Investing.com Canada
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - BioSpace
Amneal Resubmits New Drug Application for Migraine Treatment, Diabetes Drug Is Approved - MarketWatch
Amneal resubmits migraine autoinjector NDA, receives FDA nod for exenatide - Investing.com India
GSA Capital Partners LLP Has $452,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Senior VP Of Amneal Pharmaceuticals Sold 76% Of Their Shares - Simply Wall St
Amneal Pharmaceuticals Q3 2024 Earnings Preview - MSN
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue? - MSN
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Price Target at $10.00 - MarketBeat
Phocas Financial Corp. Reduces Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 16.3% in October - MarketBeat
Sandoz, Amneal Get Mixed Ruling in State Drug Price-Fixing Case - Bloomberg Law
Amneal stock target gets a boost, overweight on strong Q3 results - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High After Analyst Upgrade - MarketBeat
Piper Sandler Raises Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $11.00 - MarketBeat
AMRX Stock Soars to 52-Week High, Reaching $8.97 Amid Growth - Investing.com
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price - Simply Wall St
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Earnings call: Amneal Pharmaceuticals sees a 13% revenue surge in Q3 2024 - Investing.com
Amneal Delivers On Biosimilars Ambitions With Neupogen Rival - Citeline News & Insights
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates - MSN
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call Transcript - MSN
1.61%
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):